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The effect of tea tree oil (TTO), cumin oil (CO), rose oil (RO) and aloe vera oil (AVO) on the
skin permeation of losartan potassium (LP) was investigated. In vitro skin permeation
studies were carried out using rat skin. The mechanism of skin permeation enhancement
of LP by essential oils treatment was evaluated by FTIR, DSC, activation energy measure-
ment and histopathological examination. Both concurrent ethanol/enhancer treatment
and neat enhancer pretreatment of rat SC with all the oils produced significance increase
in the LP flux over the control. The effectiveness of the oils as the penetration enhancers
was found to be in the following descending order: AVO > RO > CO > TTO. However, only
AVO was the only enhancer to provide target flux required to deliver the therapeutic
transdermal dose of LP. FTIR and DSC spectra of the enhancer treated SC indicated that
TTO, CO, RO and AVO increased the LP permeation by extraction of SC lipids. The results of
thermodynamic studies and histopathological examination of AVO treated SC suggested
additional mechanisms for AVO facilitated permeation i.e. transient reduction in barrier
resistance of SC and intracellular transport by dekeratinization of corneocytes which may
be attributed to the presence of triglycerides as constituents of AVO. It is feasible to deliver
therapeutically effective dose of LP via transdermal route using AVO as penetration
enhancer.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.fax: þ91 11 26059663.
aahad@ksu.edu.sa (A. Ah
g Pharmaceutical Univer
sevier
University. Production anad), aqilmalik@yahoo.com (Mohd. Aqil).
sity
d hosting by Elsevier B.V. All rights reserved.
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 6 0e2 6 7 2611. Introduction
Hypertension is the most common cardiovascular disease
worldwide; hypertension is cited as the leading cause of non-
communicable disease mortality worldwide. It is a progressive
disorder, which if not effectively managed results in a greatly
increased probability of coronary thrombosis, strokes and renal
failure. Moreover, it requires long-term treatment that may
result in poor patient compliance with conventional dosage
formsdue to greater frequencyofdrugadministration [1]. These
findings suggest that despite the availability of a plethora of
therapeutically effective antihypertensive molecules, inade-
quate patient welfare is observed; this arguably presents an
opportunity to deliver antihypertensive agents through a
different route.Skin isacomplexorgan that serves toprotect the
living organisms from chemical, physical, and biological intru-
sion. In an average adult it covers an area of about 1.73 m2 and
receives one third of circulating blood through the body at any
given time. Thus, it presents an excellent opportunity for sys-
temic delivery of active pharmaceutical ingredients [2].
Transdermal delivery of drugs promises many advantages
over oral or intravenous administration, though human skin
provides an effective barrier to the permeation of most drugs
in the form of stratum corneum (SC) [3,4]. Success of the
transdermal route depends on the ability of drugs to breach
this barrier and permeate the skin at a rate sufficient to attain
effective plasma concentration. There are many approaches
were employed to enhance the skin permeation rate of active
moieties. However, the most convenient and widely imple-
mented approach is the use of chemical penetration en-
hancers [5,6] such as DMSO, DMF, azone, ionic surfactants, but
their use are also associated with unpleasant and toxic side
effects. In recent years there has been a search for natural
compounds as permeation enhancers to improve drug
permeation that also exhibit low toxicity while maintaining
their enhancing activity.
The natural absorption promoters documented so far
include essential oils, terpenes, terpenoids, fatty acid esters,
fatty acid glycols, and herbal extracts. The essential oils are
nontoxic, non-allergic, andcompatiblewithdrugandexcipients
have received much attention of researchers and found one of
the promising groups of candidates to be employed as clinically
acceptable penetration enhancers. Essential oils present a large
range of chemically acceptable and relatively safe penetration
enhancers to aidpercutaneousdrugdeliveryandareconsidered
as GRAS (generally regarded as safe) compounds for medicinal
use. They have been reported to use for permeation enhance-
ment of both hydrophilic and lipophilic drugs. They cause no
skin toxicity or if any, onlymild irritation [7].
Very recently, Patil and Saraogi, reviewed the details of
different natural products including essential oils as potential
permeation enhancer for transdermal delivery of various ac-
tives [8]. Antecedently, the feasibility of natural oils viz. corn
(maize) oil, groundnut oil and jojoba oil as penetration
enhancer was reported for enhanced transdermal olanzapine
delivery [9]. The author claimed that the magnitude of flux
enhancement factor with corn oil, groundnut oil and jojoba oil
was 7.06, 5.31 and 1.9 respectively at 5mg/ml concentration in
solvent system. Amongst the oil used, corn oil containingunsaturated fatty acids was found to be promising natural
permeation enhancer for transdermal delivery of olanzapine
with greatest cumulative amount of drug permeated
(1010.68 mg/cm2/h) up to 24 h and caused no skin irritation. In
this quest, the present work was carried out to monitor the
effect of commonly used essential oils namely, tea tree oil
(TTO), cumin oil (CO), rose oil (RO) and aloe vera oil (AVO) on
skin permeation of losartan potassium (LP) and to elucidate
the mechanism of skin permeation enhancement.
The interactions of penetration enhancers with SC lipids
and proteins (mechanism of permeation) can be elucidated
with instrumental methods such as Fourier transform
infrared (FTIR) spectroscopy and differential scanning calo-
rimetry (DSC). FTIR provides the information about the mo-
lecular and conformational changes of lipids and proteins,
whereas the DSC provides the information about their ther-
motropic behavior [10]. FTIR and DSC techniques were used to
investigate the mechanism of LP permeation in presence of
test enhancers.
Briefly, LP (Biopharmaceutics classification system class 3
drug) is an orally active angiotensin II receptor antagonist
indicated for the treatment of hypertension. The normal daily
dose of LP is 50mg and in case of severity 100mg dose is given.
The drug possesses extensive hepatic first pass metabolism
(67%) and short biological half-life (2 h) [11,12]. Therefore, LP
bypass hepatic first pass metabolism, hence its dose can be
reduced in transdermal formulation significantly. All these
properties, such as extensive hepatic first pass metabolism
(67%), short biological half-life (2 h), low dose (25e50 mg), low
oral bioavailability (33%), log P¼ 4.5, and lowmolecular weight
(461.01 Da), make it suitable for transdermal drug delivery
system [13e16]. In the present study, TTO, CO, and RO were
selected as essential oils and these were compared with AVO
as penetration enhancers to promote the percutaneous ab-
sorption of LP.2. Materials and methods
2.1. Materials
LP was received as gratis sample from Ranbaxy Research
Laboratories Ltd, Gurgaon, India. All the investigated oils
namely tea tree oil (TTO), cumin oil (CO), rose oil (RO) and aloe
vera oil (AVO) were purchased from authentic source (Sig-
maeAldrich Chemicals Private Limited New Delhi, India).
Sodium chloride, Sodium Hydroxide, ethanol, Potassium sul-
fate, Sodium azide and Sodium bromide were purchased from
S.D. Fine chemicals, India. Potassium dihydrogen orthophos-
phate were purchased from Merck India Ltd. India. High-
performance liquid chromatography (HPLC) grade acetoni-
trile andmethanol were purchased from Spectrochem Pvt Ltd,
Mumbai, India. All other chemicals used were of reagent
grade. All materials were used as received. Double distilled
water was used for all experiments.
2.2. Animals
Wistar rats (200e250 g) were supplied by Central Animal
House of Hamdard University and inhabited under standard
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Animals were nourished with pellet diet (Lipton, India) and
water ad libitum. The animals were received after the study
was duly approved by the University Animal Ethics Commit-
tee, and CPSCEA (Committee for the purpose of control and
supervision on experiments on animals), Government of
India.
2.3. Preparation of rat skin and in vitro skin permeation
studies
Wistar rats were sacrificed with prolonged ether anesthesia;
the abdominal skin of each rats were excised. Hairs on the
skin of animal were removed with electrical clipper; subcu-
taneous tissues were surgically removed, and dermis side was
wiped with isopropyl alcohol to remove residual adhering fat
[17,18]. The skin was washed with phosphate buffer saline
(PBS; pH 7.4), wrapped in aluminum foil and stored in a deep
freezer at 20 C until further use (used within two weeks of
preparation). On the day of experiment, skin was brought to
room temperature and skin samples were mounted over the
diffusion cells in such a way that SC side faced the donor
compartment whereas the dermis faced the receiver
compartment [4,19]. The effective diffusion area between two
half cells was 4.89 cm2 and the capacity of each half cell was
10 ml. The receiver fluid was equilibrated at 37 ± 0.5 C and
stirred with magnetic stirrer at a speed of 600 rpm [20,21]. The
in vitro permeation study was done in two following ways.
2.3.1. Study 1: donor solution containing penetration
enhancer in the vehicle
In study 1, saturated solution of LP in ethanol: PBS (1:9)
mixture with test penetration enhancer was added to the
donor compartment.
2.3.2. Study 2: skin pretreated with penetration enhancers
While in study 2, the skinwas pretreatedwith test penetration
enhancer for 2 h [22]. The oil was removed, followed by
washing the skin with distilled water blotting with a tissue
paper and drying at room temperature for 15e30 min. To the
donor compartment, saturated solution of LP in distilledwater
was added.
To both the donor and receptor solutions, sodium azide
(0.0025%, w/v) was added to prevent any microbial growth.
The samples (2 ml) were periodically withdrawn from the re-
ceptor compartment up to 24 h with replacement of fresh PBS
to the receiver phase. The samples were filtered and analyzed
for the drug content by HPLC method [23]. The HPLC system
consisted of a series LL-10AT VP pump (Shimadzu, Japan)
equipped with a UV detector. Separation was achieved using
RP-18 column (250 mm  4.6 mm I.D.). The isocratic mobile
phase consisted of phosphate buffer (pH 3): acetonitrile (60:40
v/v) was used. The flow rate was set to 1 ml/min. UV-HPLC
detection was performed at 273 nm.
2.4. Permeation enhancement mechanistic studies
2.4.1. FTIR study
On the day of experiment, skin was brought to room tem-
perature andwas treatedwith 1M sodiumbromide solution indistilled water for 4 h. The epidermis from full thickness skin
was separated using cotton swab moistened with water.
Epidermal sheet was cleaned by washing with distilled water
and dried under vacuum and examined for cuts or holes if
any. SC samples were prepared by floating freshly prepared
epidermis membrane on 0.1% trypsin solution for 12 h. Then,
SC sheets were cleaned by washing with distilled water. The
SC specimenwas cut into pieces of 1 cm2 and soaked in screw-
capped vials with 1 ml of neat test enhancer for 2 h. After
treatment with oil, the epidermal piece was blotted with tis-
sue paper and dried at room temperature for 15e30 min. FTIR
spectra were recorded on FTIR spectrophotometer in the re-
gion of 4000e400 cm1. The spectrumwas recorded before and
after the enhancer's treatment.
2.4.2. DSC study
For DSC studies, 5 mg SC samples were sealed in aluminum
hermetic pans placed in instrument. The SC samples (with or
without enhancer treatment) were scanned on a DSC6 (Perkin
Elmer, Germany). Scanning was done at the rate of 10 C/min
over the temperature range 10 Ce200 C [24].
2.4.3. Determination of activation energy
In vitro permeation studies of LP across rat skin were carried
out at various temperatures (27 C, 37 C, and 47 C of receptor
medium) after pretreatment with AVO for 2 h. Permeability
coefficients (kp) were calculated at each temperature and
subsequently log kp values were plotted against 1/T. Activa-
tion energies of LP were then calculated from Arrhenius
relationship [25,26].
log Kp ¼ Eact=2:303 RTþ log p0
where Eact is the activation energy, R is gas constant
(1.987 K cal/mol), and T is the temperature in K, p0 is the
Arrhenius factor.
2.4.4. Histopathological studies
Histopathological studies were carried out for elucidation of
mechanism of penetration enhancement and skin irritation
potential of the investigated enhancer. In this study, the skin
hairs of an albino rat was removed using electrical clipper and
skin was treated with AVO for 24 h. After 24 h, rat was sacri-
ficed and the skin samples from treated and untreated (con-
trol) area were taken. Each specimen was stored in 10%
formalin solution in PBS. The specimen was cut into sections
vertically. Each section was dehydrated using ethanol,
embedded in paraffin for fixing, and stainedwith hematoxylin
and eosin. These samples were then observed under light
microscope (Motic, Japan) and compared with control sample.
In each skin sample, three different sites were scanned and
evaluated for elucidation of mechanism of penetration
enhancement [3,4,27].2.5. Data analysis
Flux is the rate of change of the cumulative amount of drug
passes per unit area and time through the skin. The flux was
determined as the slope of steady state portion of the curve
between the cumulative amounts of drug permeated (mg/cm2)
Table 1 e Skin permeation parameters of LP using rat skin treated with ethanol: PBS mixture containing investigated
penetration enhancer (Study 1) and pretreated rat skin with the penetration enhancers (Study 2).
Penetration enhancer Flux (mg/cm2/h) Pb  105 (cm/h) Enhancement ratio % increase in flux Lag time (h)
Study 1a Study 2b Study 1a Study 2b Study 1a Study 2b Study 1a Study 2b Study 1a Study 2b
Controlc 255 ± 1.7d 220 ± 1.7d 41.57 35.86 1 1 e e 2.22 ± 0.5 2.26 ± 0.6
TTO 261 ± 1.1e 226 ± 1.7e 42.38 36.84 1.02 1.05 2.35 2.72 0.62 ± 0.10 0.66 ± 0.11
CO 287 ± 1.2f 283 ± 5.7f 46.78 46.13 1.13 1.31 12.54 28.64 0.32 ± 0.03 0.30 ± 0.02
RO 343 ± 1.7f 372 ± 1.1f 55.91 60.64 1.34 1.73 34.51 69.09 0.12 ± 0.01 0.08 ± 0.01
AVO 349 ± 2.3f 510 ± 2.8f 56.89 83.13 1.36 2.36 36.86 131.8 0.05 ± 0.005 0.005 ± 0.002
eNon-significant (P > 0.05).
fSignificant (P < 0.05).
a Study 1: Donor solution containing ethanol: PBS (1:9) and penetration enhancer.
b Study 2: SC pretreated with the penetration enhancers for 2 h.
c Respective controls were subjected to same treatment except penetration enhancer.
d Mean ± SEM values of three observations.
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lated by dividing the flux by the initial drug concentration per
unit area of the skin (mg/cm2). The enhancement ratio (ER) was
calculated by dividing kp in presence of enhancer by kpwithout
enhancer (control).
Therapeutic transdermal daily dose (Td) of LP was calcu-
lated by the following equation [24].
Td ¼ Do  F=100
where, F is the bioavailability in percentage after oral
administration (33% for LP) and Do is the oral dose (25 mg
for LP).
The permeated daily dose (Dss) was calculated from the
following equation.
Dss ¼ J Ta  t
where, J is the LP flux in mg/cm2/h, Ta is the area of diffusion
and t is the duration of treatment.2.6. Statistics analysis
The data was subjected to one-way analysis of variance
(ANOVA) followed by Dunnett's test using GraphPad Prism
version 3.00 for Windows (San Diego, CA, USA). Statistical
significance will be assumed when P  0.05.Fig. 1 e Skin permeation profile of LP on concurrent
treatment of test penetration enhancers with saturated
solution of LP in the vehicle i.e. ethanol: PBS (1:9) (Study 1).3. Results and discussion
3.1. In vitro skin permeation studies
The results of in vitro skin permeation studies revealed that
the flux of LP from saturated aqueous solution without
enhancer (control) was 220e255 mg/cm2/h (Table 1). This rate
of skin permeation would enable 6.45 mg of LP absorbed in
24 h which is well short of daily transdermal therapeutic dose
of LP (8.25 mg). In order to enhance the transdermal flux of LP
across the rat skin various essential oils namely TTO, CO, RO
were evaluated for their permeation enhancement potential.
Two different sets of skin permeation studies were carried
out. In study 1 (Fig. 1), 5% v/v of test enhancer was added to thesaturated solution of LP in the vehicle i.e. ethanol: PBS (1:9)
and themixturewas placed in the donor cell. In study 2 (Fig. 2),
SC was pretreated with test penetration enhancer and then
exposed to saturated solution of LP in the vehicle kept in the
donor cell. The two studies were conducted to compare the
effectiveness of the penetration enhancer pretreatment and
concurrent vehicle-enhancer treatment of SC.
In study 1 (Table 1), all the essential oils-vehicle treatments
produced significant differences (P < 0.05) in the LP flux over
the control with the exception of TTO (P > 0.05). Individual
comparison between the enhancer-vehicle treatments
revealed highly significant difference (P < 0.001) in case of
TTO-ethanol vs CO-ethanol, CO-ethanol vs RO-ethanol and
RO-ethanol vs TTO-ethanol.
The results of the study 2 (enhancer pretreatment) indi-
cated similar pattern of permeation enhancement. Highly
significant increment in LP flux (P < 0.001) was obtained by the
essential oils pretreatment over the control except TTO
(P > 0.05). On individual comparison between various pre-
treatments, highly significant difference (P < 0.001) was
observed between TTO vs CO., CO vs RO and RO vs TTO
(Table 1).
Inter study comparison presented a significant difference
(P < 0.05) between the LP flux obtained on concurrent vehicle-
Fig. 2 e Skin permeation results of LP on pretreatment with
penetration enhancers followed by treatment with
saturated solution of LP in the vehicle i.e. ethanol: PBS (1:9)
(Study 2).
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(study 2) for all the oils except in case of CO (Table 1).
The results of the above two studies suggested the effec-
tiveness of investigated essential oils as penetration enhancer
in the following order: RO > CO > TTO. As RO contains oxygen
containing hydrophilic terpenes (citronellol, geraniol, nerol,
farnesol, geranic acid and eugenol), it has emerged as the
most effective absorption promoter amongst the test essential
oils for LP, a hydrophilic drug. The results are in conformity
with previous reports [28e30]. Although RO was found to be
most effective penetration enhancer for LP and it significantly
enhanced the LP flux over the control, however it failed to
produce the target flux required to deliver the required ther-
apeutic dose for 24 h.
In the light of above observations, literature was reviewed
for other probable penetration enhancer to achieve the ther-
apeutic dose of LP delivered by the transdermal route. Our
search led to US patent: 6746689, by Wilfried et al. [31], which
claimed the use of aloe vera as the topical penetration
enhancer for delivering the required amount of a local anes-
thetic intradermally. However there are no reports on the use
of aloe vera products as the systemic penetration enhancers
for transdermal use. Hence, we investigated the feasibility of
therapeutically effective transdermal delivery of LP using AVO
as the penetration enhancer.Fig. 3 e Comparison of enhancement ratio between Study 1
and Study 2.Our results demonstrate that there was 1.36 fold and 2.36
fold enhancement in LP flux by AVO over the control in study 1
and study 2, respectively (Fig. 3). Thus, AVO was found to be
the more effective penetration enhancer for LP than all the
test essential oils. The AVO pretreatment of SC produced a
target flux of 510 mg/cm2/h which would allow required ther-
apeutic dose of LP (8.25 mg) delivered transdermally in 24 h.
3.2. Permeation enhancement mechanistic studies
3.2.1. FTIR study
The FTIR spectrum of untreated SC shows various peaks due
to molecular vibrations of lipids and proteins in the SC. The
absorption bands from 3000 to 2700 cm1 are due to the CeH
stretching motions of the alkyl groups present in both pro-
teins and lipids. The signal linked to proteins is a broad band,
rather weak compared to the lipids absorption which exhibits
four peaks at around 2850 cm1, 2920 cm1, 2870 cm1, and
2955 cm1 [29]. The bands at 2920 and 2850 cm1 are due to the
asymmetric CH2 and symmetric CH2 vibrations of long chain
hydrocarbons of lipids, peaks at 2955 cm1 and 2870 cm1 are
due to the asymmetric and symmetric CH3 vibrations
respectively [32]. These narrow bands are attributable to the
long alkyl chains of ceramides, cholesterol and fatty acids,
which are themajor components of the SC lipids. FTIR spectra
of SC treated with each oil decreased the height and area of
CH2 stretching, indicating that the lipids were extracted from
SC by all the penetration enhancers (Fig. 4) though the lipid
extraction was higher with RO and AVO.
The two strong bands at 1650 and 1550 cm1 are due to the
amide I and amide II stretching vibrations of SC proteins. The
amide I bands arises from C]O stretching vibration and the
amide II bands fromCeNbending vibration. The amide I band,
consisting of component bands, represents various secondary
structures of keratin.
The change in amide I stretching peak on treatment with
penetration enhancers is due to the extraction of proteins
(Fig. 5). The frequencies of amide bands especially amide I are
sensitive to shift to higher or lower frequencies according to
the change in protein conformation [24]. The amide I bandFig. 4 e FTIR spectra of rat skin after treatment with
penetration enhancers. Changes in lipid CeH stretching
(2920 cm¡1) vibrations; the spectra are arranged from top to
bottom: a-1; control, a-2; TTO. Pretreated SC, a-3; CO.
pretreated SC, a-4; RO pretreated SC, a-5; AVO pretreated
SC.
Fig. 5 e FTIR spectra of rat skin after treatment with
penetration enhancers. Changes in amide I (1640 cm¡1)
and amide II (1550 cm¡1) vibrations. The spectra are
arranged from top to bottom: a-1; control, a-2; TTO
pretreated SC, a-3; CO pretreated SC, a-4; RO pretreated SC,
a-5; AVO pretreated SC.
Fig. 6 e DSC thermogram of rat skin showing from top to
bottom, a-1; control, a-2; TTO pretreated SC, a-3; CO
pretreated SC, a-4; RO pretreated SC, a-5; AVO pretreated
SC.
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 6 0e2 6 7 265consisting of component bands represents various secondary
structures of keratin. As the frequency of the amide I band
shifted to higher wave number in comparison to control (un-
treated SC) (Fig. 5). It is proposed that the essential oils and the
AVO used in the present study enhanced the permeation of LP
by extraction of SC lipids as well as changes in the protein
conformations.
3.2.2. DSC study
To further substantiate the mechanism of permeation
enhancement, DSC studies were performed. DSC thermogram
of untreated SC (control) is shown in (Fig. 6). The first transi-
tion T1 shows up at around 30 C. The second and third
endotherm T2 & T3 appear at 62 C and 101 C. The first tran-
sition T1 (having the lowest enthalpy) has been attributed to
sebaceous secretion or surface contaminations and to minor
structural rearrangement within the lipid bilayer [33].
Previous studies have proposed that these transitions are
not related to lattice packing variations and assigned it to solid
to liquid phase changes for a discrete subset of SC lipids. The
second endotherm T2 is attributed to melting of lipids bilayers
[34]. Another lipid peak has been reported in previous studies
at 79 C and 83 C [34]. But it was not observed in our experi-
ment. The origin of T3 has been debatable, although recent
reports suggest that lipids in the SC are heterogeneously ar-
ranged and T3 might reflect another lipid component. The
fourth endothermwhich appears at around 100 C (which was
T3 in our case) has been attributed to intracellular keratin
denaturation and is usually heat irreversible [35].
T1 endotherm is usually ignored because it might not be
conclusive in assigning the possible mechanism of skin
permeation as it reflects the already compromised state of SC
due to solid to liquid phase changes which occur as a natural
physiology of the skin. There were definite changes in T2 and
T3 peaks indicative of extraction of lipid bilayers on each
enhancer treatment as compared to control SC (Fig. 6) except
TTO which produced only minor changes in T3 peak. T3endotherm disappeared completely in case of AVO which
might be assigned to keratin extraction in corneocytes. This
suggests the possible intracellular permeation route for LP
through corneocytes. The DSC analysis confirms that all the
penetration enhancers investigated in the present study
enhance the permeation of LP by extraction of SC lipids. AVO
also enhances the LP permeation arguably by dekeratinization
of corneocytes.
All the enhancers used in our study essentially contain
terpenes/triterpenoids. The above results corroborate the
findings of previous studies that terpenes enhance the skin
permeation of the active pharmaceutical ingredients by
extraction of the lipid bilayers [36,37]. Furthermore the intra-
cellular permeation of LP in case of AVO might be due to the
presence of other constituents like triglycerides.
3.2.3. Determination of activation energy
To further substantiate the mechanism of permeation
enhancement of AVO, thermodynamic studies were per-
formed. The Arrhenius plot between log kp values vs 1/T was
found to be linear in the temperature range selected (Fig. 7),
indicating that no significant structural perturbation or phase
transition had occurred within skin membrane [21]. The Eact
values of LP permeated across rat skin calculated as the slope
of Arrhenius plot (Fig. 7) were found to be 17.29 ± 3.5 and
1.83 ± 0.21 K cal mol1 in presence of water without and with
AVO pretreatment respectively. The significant decrease
(P < 0.05) in Eact for LP transport across rat skin by AVO in-
dicates that it alters lipid bilayer fluidity.
The high Eact values required to traverse the lipid bilayer
arise from energy needed to pull molecules free of hydrogen
bonds in aqueous vehicle and this creates sufficient free vol-
ume within viscous bilayer interiors and pull drug molecules
Fig. 7 e Arrhenius plot of LP permeation across rat skin at
different temperatures.
Fig. 9 e Photomicrograph of test skin section (enhancer
treated) showing generally normal skin structure except
for absent keratin layer.
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bilayer [38]. Alteration of any of these processes may lead to
production of Eact for transdermal permeation. Accordingly,
reduction of Eact of LP permeation by AVO may be assigned to
the disruption of hydrogen bonding of drug molecule with SC
lipids or by creating pre volume in the lipid alkyl chain.
Moreover, very low Eact of LP transport (1.83 K cal/mol) in
presence of AVO suggests that AVO creates new polar path-
ways by interacting at polar head group region of SC lipids
bilayer.
3.2.4. Histopathological studies
Fig. 8 shows the photomicrograph of the control (untreated)
skin with the well defined epidermal and dermal layers. SC is
presenting a layer of distinct keratinized cells (corneocytes).
Skin appendages (hair follicles) are clearly visible. On treating
the rat skin with the AVO, distinct changes in the keratinizedFig. 8 e Photomicrograph of control skin section (not
treated with enhancer) showing normal skin structure.
Epidermal and dermal layers are well defined.layer were observed (Fig. 9). Corneocytes were disrupted
losing the keratin and proteins. There was no effect on the
keratinized cells present in the follicles and the layers of
viable epidermis. Dermis and skin appendages were found to
be intact. The above observations clearly demonstrate the
possibility of transcellular skin transport of LP by AVO evi-
denced by dekeratinization of corneocytes present in the SC
(Fig. 9). There were no signs of skin irritation (e.g. edema, er-
ythema and inflammation) when the rat skin treated with the
AVO and the changes observed in the topmost layer (SC) could
be attributed to the action of the penetration enhancer (AVO)
only.4. Conclusion
Findings of the above study demonstrate that it is possible to
achieve enhanced LP flux by test essential oils (RO, CO, TTO)
and AVO. However, only AVO pretreatment provided the
target flux required to deliver therapeutic dose of LP percu-
taneously. FTIR and DSC analysis confirm that all investigated
penetration enhancers enhance the permeation of LP by
extraction of lipid bilayers in SC. It is concluded that it is
feasible to deliver therapeutically effective dose of LP via
transdermal route using AVO as penetration enhancer.r e f e r e n c e s
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